Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12332279 | 0.78 | LMNA (0.38) | LMNATHPOCYP1A2 | |
| SCHEMBL51260 | 0.78 | EBP (0.41) | SPHK1GBA1 | |
| SCHEMBL51615 | 0.76 | EBP (0.38) | GBA1 | |
| SCHEMBL28559828 | 0.76 | DAGLA (0.32) | CYP2D6SPHK1GMNNLMNAPOLB | |
| SCHEMBL11960077 | 0.73 | GPR84 (0.39) | SPHK1GBA1 | |
| SCHEMBL18658557 | 0.73 | — | — | |
| SCHEMBL15381137 | 0.72 | SPHK1 (0.39) | CYP2D6SPHK1GMNNLMNAPOLB | |
| SCHEMBL12302384 | 0.72 | DAGLA (0.38) | CYP2D6SPHK1GMNNLMNAPOLB | |
| SCHEMBL16559181 | 0.72 | DAGLA (0.38) | CYP2D6SPHK1GMNNLMNAPOLB | |
| SCHEMBL11981257 | 0.71 | GBA1 (0.37) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227781-A1 | Glycolipid Derivative and Drug Containing the Same as Active Component | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-1905766-A1 | GLYCOLIPID DERIVATIVE AND THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Japan as represented by President of National Center of Neurology and Psychiatry (JP) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227781-A1 | Glycolipid Derivative and Drug Containing the Same as Active Component | CD4, UGCG, HRH2 | CYP2D6 678/4885SPHK1 135/4885GMNN 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.